ProShares UltraShort NASDAQ Biotechnology
7 hedge funds and large institutions have $1.99M invested in ProShares UltraShort NASDAQ Biotechnology in 2020 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 2 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
30% more capital invested
Capital invested by funds: $1.54M → $1.99M (+$457K)
3.66% more ownership
Funds ownership: 12.43% → 16.09% (+3.7%)
22% less funds holding
Funds holding: 9 → 7 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $4K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$740K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$140K |
| 3 |
WP
WealthSource Partners
San Luis Obispo,
California
|
+$57.5K |
| 4 |
Morgan Stanley
New York
|
+$7.09K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$3.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$329K |
| 2 |
LC
Lindbrook Capital
Calabasas,
California
|
-$72K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$19.2K |
BIS Hedge Fund Activity: Q3 2020 in Review
7 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q3 2020, worth a combined $1.99M — up 30% from $1.54M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of BIS and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 5 added.
The largest buyer was HRT Financial, adding an estimated $740K. The largest seller was Tower Research Capital (TRC), cutting an estimated $329K.
- 7 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q3 2020, down from 9 in Q2 2020.
- Funds reported $1.99M of ProShares UltraShort NASDAQ Biotechnology stock for Q3 2020, up 30% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q3 2020 and 2 closed out, a net change of -2 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q3 2020 was HRT Financial, an estimated $740K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q3 2020 was Tower Research Capital (TRC), an estimated $329K sold.
Based on aggregated 13F filings for Q3 2020.